SHANGHAI, April 19, 2025 /PRNewswire/ -- The 2025 "Shanghai Summer" International Consumption Season officially launched on 18 April at Xujiahui Centre. With innovative offerings like the "240-Hour Products" and "City Customised Events," this year's programme presents a city-level consumer experience that blends international lifestyle with summer vitality. The first stop of the global roadshow will arrive in Osaka, Japan this May, continuing to share Shanghai's summer story with international audiences.
A new wave of flagship events is set to unfold. Three globally popular IPs—LEGO China， POP MART, and Shanghai Disney Resort—will join forces in Shanghai. The LEGO China Discovery Resort will enter trial operations, with the " World Play Festival" making its global debut. POP MART will bring its "Summer Trend Play" series to life, featuring IP exhibitions, new product launches, and interactive pop-ups. Shanghai Disney Resort will also unveil various summer-themed activations, creating immersive entertainment experiences for all ages.
To enhance inbound tourism, "Shanghai Summer" integrates transportation, attractions, and retail districts into a "starter kit" experience tailored for international travellers. China Eastern Airlines will offer discounted group packages across global routes. In terms of payment, Visa is co-developing "Payment-Friendly Zones" to enhance QR code transactions and tax refund scenarios for international travelers. China UnionPay is expanding foreign card acceptance to 65,000 merchants citywide and has launched the "Shanghai Summer" themed card along with a variety of promotional offers—creating a diversified payment ecosystem that integrates credit cards, mobile payments, and digital RMB.
In 2024, offline spending in Shanghai reached RMB 815.9 billion, an 8.2% increase year-on-year. Dining consumption rose to RMB 96.4 billion, up 26.9%. Foreign card spending surged by 68.2%, with Huaihai Road seeing a 208.6% increase and the Lujiazui-Zhangyang Road area growing by 119.9%—demonstrating the city's growing international appeal.
The official website www.shanghaisummer.com is now available in five languages. AI assistant "Shanghai Xiaoxia" is also online, with many offerings equipped with Japanese-language support—welcoming global travellers to join this vibrant summer celebration in Shanghai.
Media Contact: Lulu media@shanghaisummer.com
Photo: https://mma.prnasia.com/media2/2667335/Shanghai_Design_Week.jpg?p=medium600
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Shanghai Summer: A One-of-a-Kind Seasonal Experience
First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research
FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the expansion of its NULISAseq™ CNS Disease Panel 120 to include novel assays for brain-derived phosphorylated tau (pTau) proteins. The enhanced panel now features brain-derived pTau217, pTau181, pTau231, and total tau (tTau) protein measured directly from blood samples—delivering unprecedented sensitivity and specificity for the study of neurodegenerative diseases.
Phosphorylated tau has emerged as a critical biomarker for early detection and monitoring of Alzheimer's disease and other tauopathies. The new additions to the CNS Disease 120 Panel are specifically designed to detect brain-derived forms of pTau, overcoming the limitations of current assays that cannot distinguish between peripheral and central tau species. This allows for the simultaneous measurement of two suites of multiple pTaus and tTau species, one specific for brain-derived and one combining brain- and peripheral tissue-derived Tau species.
"Researchers have long sought a reliable, blood-based solution to track brain-derived tau pathology," said Dr. Yuling Luo, CEO, Founder and Chairman of Alamar Biosciences. "By integrating assays for pTau217, pTau181, pTau231, and total tau into our NULISAseq CNS Disease 120 Panel, we are enabling scientists to explore the full spectrum of tau pathology with exceptional sensitivity and throughput. This advancement is poised to accelerate biomarker-driven research and drug development in Alzheimer's Disease and related neurodegenerative disorders."
"The ability to detect brain-derived pTau species directly from blood represents a transformative step in the early detection and monitoring of Alzheimer's Disease (AD) and related disorders," said Nicholas Ashton, Ph.D., Director of Neurodegenerative Biomarker Research at Banner Health. "Until now, we've been unable to differentiate between brain-derived and peripheral pTaus in a multiplexed manner. Recent evidence has underlined the importance of being able to detect brain-derived pTau for greater specificity for AD. Alamar's new CNS panel offers an unprecedented opportunity to further improve the diagnostic accuracy and clinical utilities of these biomarkers, which will dramatically impact patient care and clinical research."
Alamar Biosciences remains committed to partnering with the neuroscience community to unlock biomarker insights that drive earlier diagnosis, patient stratification, and therapeutic monitoring.
For more information about the NULISAseq CNS Disease Panel 120 and Alamar Biosciences' portfolio of proteomic solutions, visit www.alamarbio.com.
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company's proprietary NULISA Platform along with the ARGOâ„¢ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays
